US BANCORP \DE\ - NEOLEUKIN THERAPEUTICS INC ownership

NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 87 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.33 and the average weighting 0.0%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of NEOLEUKIN THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$36,807
+18.6%
44,3460.0%0.00%
Q1 2023$31,042
+190.4%
44,346
+111.2%
0.00%
Q4 2022$10,689
-17.8%
21,0000.0%0.00%
Q3 2022$13,000
-40.9%
21,0000.0%0.00%
Q2 2022$22,000
+4.8%
21,000
+90.9%
0.00%
Q1 2022$21,000
+2000.0%
11,000
+6607.3%
0.00%
Q3 2021$1,0001640.00%
Other shareholders
NEOLEUKIN THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Opaleye Management Inc. 1,047,300$5,048,0001.07%
ACT CAPITAL MANAGEMENT, LLC 212,500$1,024,0000.74%
Redmile Group, LLC 3,490,835$16,826,0000.38%
Kynam Capital Management, LP 147,000$709,0000.38%
EcoR1 Capital, LLC 860,619$4,148,0000.13%
Baker Brothers Advisors 3,821,740$18,421,0000.09%
GSA CAPITAL PARTNERS LLP 130,899$631,0000.08%
Sio Capital Management, LLC 38,312$185,0000.06%
Highland Private Wealth Management 46,999$227,0000.03%
XTX Topco Ltd 10,018$48,0000.03%
View complete list of NEOLEUKIN THERAPEUTICS INC shareholders